Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Equity Average (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Equity Average for 9 consecutive years, with $700.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 5.59% to $700.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $700.4 million, a 5.59% decrease, with the full-year FY2025 number at $704.5 million, up 8.8% from a year prior.
  • Equity Average was $700.4 million for Q4 2025 at Iovance Biotherapeutics, roughly flat from $700.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $771.0 million in Q3 2024 to a low of $511.0 million in Q1 2023.
  • A 3-year average of $677.7 million and a median of $700.4 million in 2025 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: grew 23.75% in 2024, then dropped 9.16% in 2025.
  • Iovance Biotherapeutics' Equity Average stood at $629.3 million in 2023, then rose by 17.9% to $741.9 million in 2024, then decreased by 5.59% to $700.4 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Equity Average are $700.4 million (Q4 2025), $700.4 million (Q3 2025), and $733.2 million (Q2 2025).